Japan Connected Drug Delivery Devices Market

Japan Connected Drug Delivery Devices Market Insights Forecasts to 2035

• The Japan Connected Drug Delivery Devices Market Size Was Estimated at USD 370.99 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 22.84% from 2025 to 2035
• The Japan Connected Drug Delivery Devices Market Size is Expected to Reach USD 3564.8 Million by 2035

According To a Research Report Published By Decision Advisors & Consulting, The Japan Connected Drug Delivery Devices Market Size Is Anticipated To Reach USD 3564.8 Million By 2035, Growing At a CAGR of 22.84% from 2025 to 2035. Japan connected drug delivery devices market is growing due to an increase in older people becoming sick with chronic illnesses, and through the increasing number of government support programmes for self-administration-based devices, there will be a continued demand for technology focused on the care of elderly patients and the development of smarter, safer, more user-friendly devices.  

Market Overview

The Japan connected drug delivery devices market consists of digital technology devices such as smart inhalers and auto-injectors for the monitoring of delivery of medications and patient compliance with their medications, as well as transmitting data via wireless connectivity to healthcare practitioners. The growth of the Japanese connected drug delivery devices market is largely attributed to the country's aging population, high rates of chronic disease, and government support for self-administration technologies and personalized medicine. In Japan, the key developments in the market for connected drug delivery devices include advancements in artificial intelligence (AI) and digital health that enable the development of more accurate and tailored connected drug delivery devices, needle-free injectors, and biodegradable implants, and increased self-administration and home health care policies to support the aging population and the increase in chronic diseases.

In March 2024, the Ministry of Economy, Trade, and Industry (METI) released a strategic plan outlining the future direction for Japan's medical device industry, focusing on innovation and technological advancements.

The Ministry of Health, Labour and Welfare (MHLW) implemented reforms in April 2024 to encourage the development and early launch of innovative drugs and devices.

Report Coverage

This research report categorizes the market for the Japan connected drug delivery devices market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan connected drug delivery devices market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan connected drug delivery devices market.  

Driving Factor

The Japan connected drug delivery devices market is driven by a growing aged cohort in the country, along with an increasing incidence of chronic diseases such as diabetes and COPD, and the need for a broader array of patient-centric and remote healthcare options, are all supported by an emphasis on advances in technology within the healthcare industry and on government policies to promote patient-centric healthcare services. Technological advancements, government support for digital health and home care, and a push for personalized medicine also propel the market forward. 

Restraining Factor

The Japan connected drug delivery devices market is restrained by difficult regulatory requirements, high upfront costs associated with purchasing sophisticated devices, and large amounts of concern related to protecting patient confidentiality. A lengthy validation process can therefore restrict a manufacturer’s ability to quickly introduce their products into the marketplace.

Market Segmentation

The Japan connected drug delivery devices market share is categorized by application and route of administration.

• The diabetic management segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan connected drug delivery devices market is segmented by application into asthma, COPD, diabetes management, and others. Among these, the diabetic management segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by increasing worldwide prevalence of both Type 1 Diabetes and Type 2 Diabetes, which has primarily been attributed to the ageing population, unhealthy lifestyle choices, increased obesity levels within society, and a more sedentary lifestyle than ever before. Continuous technology advancement and innovation in diabetes care devices are also major contributing factors to this growth.

• The parenteral segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan connected drug delivery devices market is segmented by route of administration into parenteral and inhalational. Among these, the parenteral segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by resulting in an increased need for the long-term administration of very strong injectable medications. In addition, the growing use of complex, biologically-derived medications as well as their biosimilar versions, both of which nearly all need to be injected into the body, is a further major driving force in the growth of the market. There are also technological advances being made in the development of delivery systems such as prefilled syringes and automated injectors, which are enhancing the market growth for these products by providing patients with increased convenience and safety.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan connected drug delivery devices market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Terumo Corporation
• Omron Healthcare
• Tasei Kako Co., Ltd.
• Nipro Corporation
• Otsuka Pharmaceutical Co.
• Mitsubishi Tanabe Pharma Corporation
• Daiichi Sankyo Co.
• Chugai Pharmaceutical Co., Ltd.
• CureApp
• Shin Nippon Biomedical Laboratories (SNBL)
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2023, Terumo Corporation announced plans to build a new manufacturing facility at its Kofu Factory in Yamanashi, Japan. With a total investment of ¥52.2 billion, the facility is scheduled for completion in fiscal year 2025. The new site will support the company’s expanding CDMO (contract development and manufacturing) business and production of peritoneal dialysis–related products. It will also provide additional capacity to scale up manufacturing in response to future market demand. 

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the Japan Connected Drug Delivery Devices Market based on the below-mentioned segments:

Japan Connected Drug Delivery Devices Market, By Application

• Asthma
• COPD
• Diabetes Management
• Others

Japan Connected Drug Delivery Devices Market, By Route of Administration

• Parenteral
• Inhalational

FAQs

Q: What is the estimated size of the Japan Connected Drug Delivery Devices Market in 2024?

A: The market size in 2024 is estimated at USD 370.99 billion.

Q: What CAGR is the Japan connected drug delivery devices market expected to achieve from 2025 to 2035?

A: The market is expected to grow at a CAGR of 22.84% during 2025–2035.

Q: What factor is driving the strong demand for connected drug delivery devices in Japan?

A: Growth is driven by Japan’s aging population and rising chronic disease incidence, which increases the need for remote and self-administration technologies.

Q: Which application segment held the largest revenue share in 2024?

A: Diabetes management accounted for the largest revenue share in 2024.

Q: What recent development was announced by Terumo Corporation relevant to this market?

A: In May 2023, Terumo announced a ¥52.2 billion new manufacturing facility to expand CDMO and peritoneal dialysis product capacity.